Exhibit 99.1 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update • Cemacabtagene Ansegedleucel (Cema-Cel) ◦ Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) ▪ Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Bi ...